This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



daratumumab (Darzalex®)


Reference No. 4237

Publication date:
16/06/2020


Appraisal information

daratumumab (Darzalex®) 20 mg/ml solution for infusion


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, daratumumab (Darzalex®) cannot be endorsed for use within NHS Wales for use in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant
Statement of Advice (SOA)
Download